MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2022-03-31 (pharmabiz.net)
mAbxience: Fresenius buys 55% |
The forecasts brewing since last year about Insud Group selling part of mAbxience, its biopharmaceutical business dedicated to the production of monoclonal antibodies, were spot on. Germany’s Fresenius, which was always mooted as the big favourite, has reached an agreement to buy 55% of the company for an initial payment of €495 million. See Press...
Read more